Ignite Creation Date:
2025-12-24 @ 4:03 PM
Ignite Modification Date:
2026-01-04 @ 3:57 PM
Study NCT ID:
NCT04609566
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-15
First Post:
2020-10-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-26
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-23
First Submit QC Date:
None
Study First Post Date:
2020-10-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-08
Last Update Post Date:
2025-12-15
Last Update Post Date Type:
ESTIMATED